Acelyrin (SLRN) said late Thursday it has received an unsolicited indication of interest from Tang Capital Partners-backed Concentra Biosciences to acquire all of its outstanding shares for $3.00 per share in cash, plus a contingent value right to receive 80% of net proceeds from any out-license or disposition of its development programs or intellectual property.
Acelyrin said it agreed Feb. 6 to an all-stock merger with Alumis (ALMS) in a deal expected to close in Q2.
The company said its board is committed to acting in the interests of shareholders and will make a further announcement on the matter "in due course."
Shares of Acelyrin rose more than 12% in recent premarket activity Friday.
Price: 2.45, Change: +0.28, Percent Change: +12.90
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.